Insulin Lispro: The Fast-Acting Revolution | Golden Age

Insulin lispro, marketed under the brand name Humalog, is a fast-acting insulin analogue developed by Eli Lilly and Company, first approved by the FDA in 1996. This recombinant human insulin analogue has a Vibe score of 82, indicating significant cultural energy and impact. With its ability to start working within 15 minutes of injection, peaking between 30 minutes to 1 hour, and lasting approximately 2 to 4 hours, insulin lispro has revolutionized diabetes management for millions worldwide. However, controversy surrounds its high cost and accessibility, particularly in low-income countries, with some critics arguing that pharmaceutical companies prioritize profits over patient needs. Despite these challenges, insulin lispro remains a crucial tool in the fight against diabetes, with ongoing research focused on improving its affordability and efficacy. As the diabetes epidemic continues to grow, the influence of insulin lispro will only continue to expand, with a projected global market value of over $10 billion by 2025.